130 related articles for article (PubMed ID: 34688151)
21. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.
Herth FJF; Sakoulas G; Haddad F
Respiration; 2020; 99(12):1145-1153. PubMed ID: 33316806
[TBL] [Abstract][Full Text] [Related]
22. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
24. Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States.
Gupta S; Kaushik A; Gupta J
Monaldi Arch Chest Dis; 2020 Oct; 90(4):. PubMed ID: 33059413
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial.
Fakharian A; Barati S; Mirenayat M; Rezaei M; Haseli S; Torkaman P; Yousefian S; Dastan A; Jamaati H; Dastan F
Int Immunopharmacol; 2021 Oct; 99():107961. PubMed ID: 34426106
[TBL] [Abstract][Full Text] [Related]
26. COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes.
Banai A; Taieb P; Furie N; Hochstadt A; Merdler I; Sapir O; Granot Y; Lupu L; Ghantous E; Borohovitz A; Gal-Oz A; Ingbir M; Arbel Y; Banai S; Topilsky Y; Lichter Y; Szekely Y
Intern Emerg Med; 2021 Sep; 16(6):1629-1639. PubMed ID: 33797029
[TBL] [Abstract][Full Text] [Related]
27. Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial.
Tam AR; Zhang RR; Lung KC; Liu R; Leung KY; Liu D; Fan Y; Lu L; Lam AH; Chung TW; Yip CC; Lo J; Wu AK; Lee R; Sin S; Ng PY; Chan WM; Shum HP; Yan WW; Chan JF; Cheng VC; Lau CS; To KK; Chan KH; Yuen KY; Hung IF
Clin Infect Dis; 2023 Feb; 76(3):e216-e226. PubMed ID: 35762834
[TBL] [Abstract][Full Text] [Related]
28. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
29. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.
Alavi Darazam I; Hatami F; Mahdi Rabiei M; Amin Pourhoseingholi M; Shabani M; Shokouhi S; Mardani M; Moradi O; Javandoust Gharehbagh F; Mirtalaee N; Negahban H; Amirdosara M; Zangi M; Hajiesmaeili M; Kazempour M; Shafigh N
Int Immunopharmacol; 2021 Oct; 99():107916. PubMed ID: 34224994
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
31. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
[TBL] [Abstract][Full Text] [Related]
32. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
33. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
34. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
35. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
Best JH; Kong AM; Kaplan-Lewis E; Brawley OW; Baden R; Zazzali JL; Miller KS; Loveless J; Jariwala-Parikh K; Mohan SV
J Med Virol; 2021 Sep; 93(9):5367-5375. PubMed ID: 33913536
[TBL] [Abstract][Full Text] [Related]
36. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
39. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
40. Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
Cohan SL; Hendin BA; Reder AT; Smoot K; Avila R; Mendoza JP; Weinstock-Guttman B
CNS Drugs; 2021 Jul; 35(7):743-767. PubMed ID: 34228301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
